



Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/033,526
				Filing Date	November 2, 2001
				First Named Inventor	Y. Huang
				Group Art Unit	1647
				Examiner Name	C.J. Nichols
				Attorney Docket Number	UCAL-217
Sheet	1	of	1		

RECEIVED

DEC 30 2002

TECH CENTER 600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CSN		Huang, Y. et al., Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. PNAS, 2001, Vol. 98, No. 15, pp. 8838-8843	
CSN		Emilien, G. et al., Alzheimer Disease Mouse Models pave the way for therapeutic opportunities. Neurological Review, 2000, Vol. 57, pp. 176-181	
CSN		Huang, Y. et al., Bioactive fragments of apolipoprotein E induce neurofibrillary tangles in cultured neurons. Society for Neuroscience Abstracts, 2000, Vol. 26, No. 1-2, 202.8	

Examiner Signature		Date Considered	1/14/03
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

MAY 14 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/033,526
				Filing Date	November 2, 2001
				First Named Inventor	HUANG ET AL.
				Group Art Unit	1632
				Examiner Name	To Be Assigned
Sheet	1	of	2	Attorney Docket Number	UCAL217

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
CSN	—	6,046,381	—	Mucke, et al.	April 4, 2000	

COPY OF PAPERS
ORIGINALLY FILED

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CSN	—	Mahley and Huang (1999) <i>Curr. Opin. Lipidol.</i> 10:207-217	1
CSN	—	Dallongeville (1992) <i>J. Lipid Res.</i> 33:447-454	1
CSN	—	Slooter et al. (1997) <i>JAMA</i> 277 :818-821	1
CSN	—	Nicoll et al. (1996) <i>Neuropathol. Appl. Neurobiol.</i> 22:515-517	1
CSN	—	Selkoe (1991) <i>Neuron</i> 6:487-498	1
CSN	—	Roses, et al. (1994) <i>Curr. Opinion Biotechnol.</i> 5:663-667	1
CSN	—	Huang et al. (2001) <i>Proc. Natl. Acad. Sci. USA</i> 98:8838-8843	1

Examiner Signature	<i>J. M. [Signature]</i>	Date Considered	1/14/03
-----------------------	--------------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.